Bernhardt G Zeiher insider trades: Entrada Therapeutics (TRDA) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Bernhardt reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | TRDA | ↑ Buy | 5,000 | $5.86 | $29K | By Bernhardt G Zeiher and Paula B Zeiher | May 21, 2026 (1d) |
| Mar 20, 2025 | AMLX | ↑ Buy | 10,000 | $3.70 | $37K | Direct | Mar 24, 2025 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TRDA insiders
Open-market trades in the last 12 months
About Bernhardt G Zeiher's insider trades
Bernhardt G Zeiher is a director at Entrada Therapeutics (TRDA). Since Mar 20, 2025, Bernhardt has reported 2 open-market purchases worth $66K and no sales on SEC Form 4. In the last 12 months: 1 buy ($29K).
Their filings also include grants and awards (11 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TRDA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.